Abstract
Background Brain magnetic resonance imaging (MRI) of infants with congenital heart disease (CHD) shows brain immaturity assessed via a cortical-based semi-quantitative score. Our primary aim was to develop an infant paralimbic-related subcortical-based semi-quantitative dysmaturation score, a brain dysplasia score (BDS), to detect abnormalities in CHD infants and predict clinical outcomes. Our secondary aim was to validate our BDS in a preclinical mouse model of hypoplastic left heart syndrome.
Methods A paralimbic-related subcortical BDS, derived from structural MRIs of infants with CHD, was correlated with clinical risk factors, regional cerebral volumes, feeding and 18-month neurodevelopmental outcomes. The BDS was validated in a known CHD mouse model named Ohia with two disease-causing genes, Sap130 and Pchda9. To relate clinical findings, RNA-Seq was completed on Ohia animals.
Findings BDS showed high incidence of paralimbic-related subcortical abnormalities (including olfactory, cerebellar, and hippocampal abnormalities) in CHD infants (n=215) compared to healthy controls (n=92). BDS correlated with reduced cortical maturation, developmental delay, poor language and feeding outcomes, and increased length of stay. Ohia animals (n=63) showed similar BDS findings, and RNA-Seq analysis showed altered neurodevelopmental and feeding pathways. Sap130 mutants correlated with a more severe BDS whereas Pcdha9 correlated with a milder phenotype.
Interpretation Our BDS is sensitive to dysmaturational differences between CHD and healthy controls, and predictive of poor outcomes. A similar spectrum of paralimbic-related subcortical abnormalities exists between human and Ohia mutants suggesting a common genetic mechanistic etiology.
Funding National Library of Medicine, Department of Defense, National Heart, Lung, and Blood Institute, National Institute on Aging, Southern California Clinical and Translational Sciences Institute, Additional Ventures Foundation, Saban Research Institute, Children’s Hospital Los Angeles Clinical Services Research Grant, and National Institute of Nursing Research. Funding award numbers can be found in the acknowledgment section.
Evidence before The number of clinical and research MRI studies in neonatal/infant CHD subjects has increased dramatically in the last two decades. Previous studies have developed brain MRI scores that have focused on cortical structural maturation and acquired brain injury. Paralimbic-related subcortical regions are important for the development of cognitive and visuomotor functions in early development. Levering a large infant brain MRI dataset and a large-scale genetic mouse screen, we theorized that a paralimbic-related subcortical brain MRI score could assist clinicians with outcome prediction in CHD infants.
Added Value This work aims to develop a subcortical morphological scoring system that could be applied to either clinical or research MRI scans and could improve the ability of clinicians and neuroradiologists to predict not only those at risk for suboptimal neurodevelopmental outcomes but also associated co-morbidities. We discovered not only are there paralimbic-related subcortical structural abnormalities that a brain MRI score can detect but also that this score predicted poor language outcomes, poor feeding outcomes, and increased post-surgical length of stay. We also found that the genetic model of hypoplastic left heart syndrome, the most severe form of CHD, also demonstrated a similar pattern of paralimbic related subcortical brain abnormalities.
Implications This novel scoring system developed by our group has implications for early detection of at-risk CHD individuals for poor outcomes, both neurodevelopmental and quality of life. This subcortical paralimbic brain dysplasia score is a simple tool that can be easily added to neuroradiological workflows that can lead to better outcome prediction for children with CHD. Our scoring system helps us to better serve our population, allowing clinicians and researchers to prognosticate highest risk individuals who will benefit from the earliest forms of intervention.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Department of Defense (W81XWH-16-1-0613), the National Heart, Lung, and Blood Institute (R01 HL152740-1, R01 HL128818-05), and the National Heart, Lung and Blood Institute with National Institute on Aging (R01HL128818-05 S1). Southern California Clinical and Translational Sciences Institute (NCATS) through Grant UL1TR0001855. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. We also acknowledge Additional Ventures for support (AP, VR, RC). VR is supported by the Saban Research Institute, Additional Ventures Foundation and NIH-NHLBI K01HL153942. NT is supported by Children's Hospital Los Angeles Clinical Services Research Grant and the NINR K23 Grant 1K23NR019121-01A1.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Children's Hospital of Los Angeles and IRB of Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center gave ethical approval for this work. The study was HIPAA compliant and approved by the institutional review board (IRB) of Children's Hospital Los Angeles (CHLA) and Children's Hospital of Pittsburgh (CHP) of the University of Pittsburgh Medical Center (UPMC) and written informed consent was obtained from each subject, except for a few patients in which MRI was obtained clinically, and retrospective use of the data was approved by the IRB protocol (CHLA-CCI-09-00055, CCI-10-00235, University of Pittsburgh-20030213,19100215, 19030204). All experiments were performed per the institutional guidelines and regulations.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors. Preclinical mouse data can be made available upon request to corresponding author. Clinical data cannot be made public due to privacy issues, but limited data can be made available upon special request to the corresponding author with justification for the data request.
Non-standard Abbreviations and Acronyms
- ECM
- Episcopic Confocal Microscopy
- CHD
- congenital heart disease
- HLHS
- hypoplastic left heart syndrome
- MRI
- magnetic resonance imaging
- WMI
- white matter injury
- GA
- gestational age
- PCA
- post-conceptional age
- BDS
- brain dysplasia score.
